<a href=Roche diab” height=”342″ src=”https://www.medicaldevice-network.com/wp-content/uploads/static-progressive/nri/medicaldevice/roche%20diab.jpg” style=”padding: 10px” width=”241″ />

The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended clearance of Denmark-based company Novo Nordisk‘s NovoRapid PumpCart in Europe.

NovoRapid is a mealtime insulin that improves glycaemic control in adults and children with diabetes.

The 1.6ml prefilled insulin pump cartridge contains Novo Nordisk’s rapid-acting insulin NovoRapid and is compatible with Roche’s Accu-Chek Insight diabetes therapy system.

Novo Nordisk marketing and medical affairs executive vice president Jakob Riis said that insulin pump users currently have to fill disposable plastic reservoirs with insulin from a larger insulin vial.

"Now, insulin pump users can simply place a prefilled insulin cartridge into their insulin pump without any extra handling steps," Riis added.

The prefilled cartridge and insulin delivery system is expected to make insulin pump therapy more convenient for people with diabetes. It has been developed in a non-exclusive partnership with Roche Diabetes Care and is expected to be launched in selected European countries during 2014 and 2015.

Roche Diabetes Care global head Luc Vierstraete said that the company is excited to be able to offer this solution to its customers and bring to market its innovative Accu-Chek insight diabetes therapy system.

"This can help to enhance the advantages of a targeted and effective insulin pump therapy while contributing to a simplified diabetes management in everyday life," he said.

According to GlobalData estimates, the insulin pumps market in Europe, valued at $176m in 2012, is expected to grow at a compound annual growth rate of 6.3% to reach $270m by 2019.

Image: Accu-Chek compact plus Photo: courtesy of F. Hoffmann-La Roche Ltd.